Cladribine, an oral immunomodulatory drug, has been denied FDA and European Medicines Agency approval for the treatment of relapsing–remitting multiple sclerosis. However, a new post-hoc analysis of CLARITY study data shows that cladribine treatment is associated with a significantly increased likelihood of sustained freedom from disease activity.
This is a preview of subscription content, log in via an institution to check access.
References
Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387–401 (2010).
Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402–415 (2010).
Giovannoni, G. et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362, 416–426 (2010).
Merck Serono. Merck Serono: regulatory update on cladribine tablets. Merck Serono [online], (2011).
Giovannoni, G. et al. Sustained disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 10, 329–337 (2011).
Gold, R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs 25, 37–52 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
R. Hohlfeld has received honoraria and grant and/or research support from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis and Teva, and has acted as a consultant for each of these companies.
Rights and permissions
About this article
Cite this article
Hohlfeld, R. Cladribine—a contentious therapeutic contender for MS. Nat Rev Neurol 7, 425–427 (2011). https://doi.org/10.1038/nrneurol.2011.105
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2011.105
- Springer Nature Limited